Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
As we age, the cells in our body gradually lose their ability to produce energy efficiently and repair damage. This process, known as cellular ageing, is linked to lower levels of a molecule called Nicotinamide Adenine Dinucleotide (NAD⁺), which is essential for energy production and maintaining healthy cell function. Other factors, such as reduced antioxidant capacity and mitochondrial decline, also contribute to ageing.
This study will explore whether a daily food supplement, taken for one month, can improve markers of cellular health in adults aged 35 and over. Thrive⁺ contains ingredients that may support energy metabolism and antioxidant defences, including compounds that boost NAD⁺ levels and Coenzyme Q10 (CoQ10), which helps cells produce energy. It also includes resveratrol, a plant compound thought to promote healthy ageing.
The research will take place at The Functional Gut Clinic in Manchester and will involve 15 healthy volunteers. Participants will attend two clinic visits: one at the start and one after 30 days of supplementation. At each visit, they will have blood tests, blood pressure and heart rhythm checks, a simple grip strength test, and complete short questionnaires on mood and wellbeing. Women of childbearing potential will also have a pregnancy test. The supplement will be taken as one capsule per day for 30 days.
The main question is whether the supplement increases NAD⁺ levels in the blood. We will also look at other markers, such as antioxidant status, inflammation, and physical measures like grip strength. The study aims to provide insight into whether supplementation can support healthy ageing in everyday life.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Longevity supplement | Experimental | This is a single arm study, with the a participants receiving the active supplement. Supplement containing Niagen NR 300mg, Trans resveratrol 250mg, Niacin (B3) 120mg, CoEnzyme Q10 100mg and Copper 0.3mg. Taken once daily. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Longevity supplement | Dietary Supplement | Supplement containing Niagen NR 300mg, Trans resveratrol 250mg, Niacin (B3) 120mg, CoEnzyme Q10 100mg and Copper 0.3mg. Taken once daily. |
| Measure | Description | Time Frame |
|---|---|---|
| Change in whole blood nicotinamide adenine dinucleotide (NAD+) | Change in whole blood NAD+ measured using Liquid chromatography mass spectrometry. Changes measured from baseline (pre supplement) to end of study (30 days of supplementation). measured in micrograms per millilitre. | 30 days |
| Measure | Description | Time Frame |
|---|---|---|
| Change in plasma NAD+ metabolites | Changes in plasma NAD+ metabolites. These include changes in Nicotinamide (NAM) and 1-Methylnicotinamide. These are both measures in milligrams (mg) using Liquid chromatography mass spectrometry. Changes to be measured from baseline to end of study. | 30 days |
| Change in total coenzyme Q10 (CoQ10) |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| The Functional Gut Clinic | Manchester | M3 4BG | United Kingdom |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Changes in plasma coenzyme Q10. This is measured in micrograms (ug) using colourimetry. Changes to be measured from baseline to end of study. |
| 30 days |
| Change in standard haematology and biochemistry blood panels | Changes in haematology and biochemistry blood panels. Changes till be assessed by a study doctor and assigned any clinical significance. Any clinical significant findings will be recorded as an adverse event. Changes will be measured from baseline to end of study. | 30 days |